Neurocrine Biosciences Inc. (NBIX) 6.46 -0.08

Neurocrine Biosciences, Inc.
(NBIX) 6.46 -0.08

Last Trade:	6.45	Day Range:	6.38 - 6.57
Trade Time:	08:05PM	52wk Range:	5.42 - 9.98
Prev. Close:	6.53	Market Cap:	427.68M
Open:	6.46	Div Yield:	0
Volume:	1102795	PE:
EPS:	0.62

The Latest On NBIX

Neurocrine Biosciences Announces Urocortin 2 Phase II Study Results in Patients With Acute Decompensated Heart Failure; Drug Generally Well Tolerated 5/17/12 4:06pm

Elagolix Endometriosis Phase III Trials on Track to Commence in Second Quarter 2012 3/27/12 8:02am

Neurocrine Announces Phase II Results of VMAT2 Inhibitor NBI-98854 for Treatment of Tardive Dyskinesia 3/26/12 4:01pm

UPDATE: Deutsche Bank Initiates Buy, $15 PT on Neurocrine 3/16/12 6:17am

Neurocrine Biosciences Announces Exercise in Full of Underwriters' Option to Purchase Additional Shares 1/30/12 5:00pm

Neurocrine Biosciences Announces The FDA Has Granted Fast Track Designation For VMAT2 Inhibitor NBI-98854 1/25/12 9:31am

Neurocrine Biosciences Prices Public Offering of Common Stock at $8.10 per Share 1/19/12 10:11am

Neurocrine Biosciences Announces Proposed Public Offering of Common Stock; No Amount given 1/18/12 5:01pm

Are Upcoming Study Results Spurring Insider Buying at Ligand Pharmaceuticals? 11/2/11 8:46am

Jefferies Has Buy on Neurocrine Bio After Earnings 11/1/11 7:50am

Neurocrine Biosciences Receives Second Milestone Payment of $20 Million Under Abbott Collaboration Agreement 10/4/11 4:05pm

Neurocrine Biosciences Announces That VMAT 2 Program Begins Enrollment in Second Phase II Clinical Trial 9/19/11 4:00pm

Neurocrine Biosciences Announces Urocortin 2 Phase II Study Results in Patients With Acute Decompensated Heart Failure; Drug Generally Well Tolerated 5/17/12

Elagolix Endometriosis Phase III Trials on Track to Commence in Second Quarter 2012 3/27/12

Neurocrine Announces Phase II Results of VMAT2 Inhibitor NBI-98854 for Treatment of Tardive Dyskinesia 3/26/12

UPDATE: Deutsche Bank Initiates Buy, $15 PT on Neurocrine 3/16/12

Neurocrine Biosciences Announces Exercise in Full of Underwriters' Option to Purchase Additional Shares 1/30/12

Neurocrine Biosciences Announces The FDA Has Granted Fast Track Designation For VMAT2 Inhibitor NBI-98854 1/25/12

Neurocrine Biosciences Prices Public Offering of Common Stock at $8.10 per Share 1/19/12

Neurocrine Biosciences Announces Proposed Public Offering of Common Stock; No Amount given 1/18/12

Are Upcoming Study Results Spurring Insider Buying at Ligand Pharmaceuticals? 11/2/11

Jefferies Has Buy on Neurocrine Bio After Earnings 11/1/11

Neurocrine Biosciences Receives Second Milestone Payment of $20 Million Under Abbott Collaboration Agreement 10/4/11

Neurocrine Biosciences Announces That VMAT 2 Program Begins Enrollment in Second Phase II Clinical Trial 9/19/11

Technical Trading Summary 6/7/2011 6/7/11

Neurocrine Biosciences: Marching to 52 Week High (NBIX) 12/22/10

ETFs For Biotech M&A Mania 12/6/10

Stocks Hitting 52-Week Highs (SMTS, CRUS, NBIX, ARUN) 6/16/10

Mid-Day Market Movers (TLCR, PDO, XFN, NBIX) 6/16/10

Neurocrine Bioscienes (NBIX) All Set To Search For Higher Top 5/25/10

Potential Volume Plays For March 5, 2010 (CNXT, BRCD, ZANE, NBIX, YMI) 3/5/10

Benzinga’s Top Pre-Market Losers (MRVL, CNXT, NBIX, SOLF, MENT) 3/5/10

UPDATE: Deutsche Bank Initiates Buy, $15 PT on Neurocrine 3/16/12

Jefferies Has Buy on Neurocrine Bio After Earnings 11/1/11

Jefferies Maintains Buy on Neurocrine Biosciences 6/24/11

Hapoalim Securities Terminates Healthcare Coverage Including Bristol-Myers, Eli Lilly, Merck and Pfizer 6/1/11

Hapoalim Cutting Ocverage On Multitude Of Names 6/1/11

Jefferies Has Buy Rating On Neurocrine Bio. (NBIX) 4/6/11

Jefferies Has Buy Rating On Neurocrine Bio. (NBIX) 3/28/11

Piper Jaffray Maintains Overweight on Neurocrine Biosciences (NBIX) 3/25/11

Hapoalim Sees Strong Upside In Neurocrine Biosciences (NBIX) 2/11/11

Jefferies Comments On Neurocrine Bio's Daisy PETAL Study 11/23/10

Hapoalim Securities Reiterates Buy Rating on Neurocrine Biosciences (NBIX) 7/29/10

Benzinga’s Top Pre-Market Gainers (FSLR, CRUS, NBIX, NVDA) 6/17/10

Trade NBIX
NOW!

Partner Headlines

Neurocrine Biosciences Inc. Reports Operating Results (10-Q) 5/2/12

Sustainable Growth indicated by Pendrell's Financials (PCO, PWER, NBIX) 3/29/12

Consider These 5 Healthcare Stocks Now 3/21/12

New Ratings ( ENDP, SPTN, DAN, SBAC, AMT, CCI, CAB, GLNG, NBIX ) 3/16/12

New Analyst Coverage ( ANGI, GLUU, HALO, AWAY, NLSN, NBIX, WPX ) 3/8/12

Value At Abbott Labs Balances A Lot Of Growth Optimism (ABT, PFE, AZN, NBIX) 2/14/12

Neurocrine Biosciences Inc. Reports Operating Results (10-K) 2/9/12

Neurocrine Biosciences (NBIX) - Bull of the Day 11/2/11

Neurocrine Biosciences Inc. Reports Operating Results (10-Q) 10/31/11

Best Biotech CEO of 2010 Is... 12/15/10

Biotech's Brighter Corners 12/8/10

Vote for the Best Biotech CEO of 2010 12/8/10

Press Releases

Neurocrine Biosciences to Present at the Jefferies 2012 Global Healthcare Conference 5/29/12 Newswire

Neurocrine Biosciences Announces Urocortin 2 Phase II Study Results in Patients With Acute Decompensated Heart Failure 5/17/12 Newswire

Neurocrine Biosciences To Present At The Deutsche Bank 37th Annual Health Care Conference 5/4/12 Newswire

Neurocrine Biosciences Reports First Quarter 2012 Results 5/2/12 Newswire

Neurocrine Biosciences Announces Conference Call and Webcast to Present First Quarter 2012 Financial Results 5/1/12 Newswire

Neurocrine Biosciences Announces Conference Call and Webcast to Present First Quarter 2012 Financial Results 4/25/12 Newswire

Neurocrine Biosciences to Present at the 11th Annual Needham Healthcare Conference 3/27/12 Newswire

Elagolix Endometriosis Phase III Trials on Track to Commence in Second Quarter 2012 3/27/12 Newswire

Neurocrine Announces Phase II Results of VMAT2 Inhibitor NBI-98854 for Treatment of Tardive Dyskinesia 3/26/12 Newswire

Neurocrine Biosciences to Present at The 24th Annual Roth Conference 3/7/12 Newswire

Neurocrine Biosciences to Present at the 32nd Annual Cowen Health Care Conference 2/29/12 Newswire

Neurocrine Biosciences to Present at the Citi 2012 Global Health Care Conference 2/21/12 Newswire

Get the latest NBIX stock news on the web. Get the latest stock quotes and much more - Benzinga is the source for Neurocrine Biosciences, Inc. stock price.

Neurocrine Biosciences, Inc. by YCharts

Neurocrine Biosciences Inc. (NBIX) 6.46 -0.08

Quotes

Analysis

Twitter

Ownership

Earnings

The Latest On NBIX

From Benzinga's Newsdesk

Benzinga's News Delivered Free

Latest from Premium

Brain Trust

Popular Channels

Tools & Features

About Benzinga

Social